Tivumecirnon besylate is under clinical development by RAPT Therapeutics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II drugs for Esophageal Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tivumecirnon besylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tivumecirnon besylate overview
Tivumecirnon (FLX-475) is under development for the treatment of metastatic gastric cancer, gastroesophageal junction adenocarcinoma, non-small cell lung cancer, triple negative breast cancer, urothelial carcinoma, gastric cancer, non-Hodgkin lymphoma, esophageal carcinoma, cervical cancer, classical Hodgkin lymphoma. The drug candidate is administered orally. It acts by targeting chemokine receptor type 4 (CCR4).
It was also under development for the treatment of colorectal adenocarcinoma and ovarian cancer, advanced melanoma, hematological malignancies, solid tumors, head and neck squamous cell carcinoma, nasopharyngeal carcinoma.
RAPT Therapeutics overview
RAPT Therapeutics is a clinical-stage immunology-based therapeutics company that discovers, develops and commercializes oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Its pipeline products include RPT193, FLX475 and HPK1. Its pipeline candidates treat inflammation and cancer. It also develops a pipeline of orally available small-molecule drugs to activate the immune system and eradicate cancer. The company has advanced into the clinic with a dual-inhibitor drug that targets FLT3 and CDK4 and 6 for the treatment of cancer. RAPT Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of Tivumecirnon besylate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
